News

EP-104GI maintains 64% remission rate at 52 weeks in eosinophilic esophagitis trial, offering a single-procedure alternative to daily therapy.

Phathom opens Phase 3 trial testing vonoprazan for non-erosive GERD as an on-demand treatment, potentially changing how the drug...

Cartesian's Descartes-08 retreatment data shows MG patients can receive repeat doses with sustained response, informing Phase 3 dosing strategy.

Immix's NXC-201 achieves 89% complete response rate in Phase 2 AL amyloidosis trial, with 40 of 45 patients showing...

Dyne's z-basivarsen shows 4.8% muscle strength improvement at one year in DM1 trial, signaling potential clinical benefit in a...

Giredestrant cuts disease progression risk 44% in ER-positive breast cancer versus standard endocrine therapy in phase III evERA trial...

EDC query automation improves data quality only when sites can respond without being overwhelmed by low-value queries.

Federal government outlines four regulatory changes for IRB oversight affecting multisite studies, protocol reviews, and institutional compliance by 2027.

NewAmsterdam Pharma doses first participant in SPINOZA Phase 2b trial of obicetrapib for preclinical Alzheimer's disease, testing a CETP...

Iopofosine I 131 achieved 79% major response in BTK inhibitor-refractory Waldenström macroglobulinemia patients in Phase 2b trial data.